MedPath

Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran)

Not Applicable
Not yet recruiting
Conditions
This study is performed on healthy volunteers and drug concentration in plasma is determined..
Registration Number
IRCT20200105046010N101
Lead Sponsor
Kharazmi Pharmacy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
24
Inclusion Criteria

General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28) kg/m^2
Informed consent
Age (18-55 years old)

Exclusion Criteria

Nicotine consumption history
Cardiovascular disease History
Liver and kidney disease History
Alcohol and opioid addiction
Allergy reactions history to Linagliptin or Metformin

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.